A Population-based and Symptom-based COVID-19 Prevalence Survey

Overview

Journal J Educ Health Promot

Specialty Medical Education

Date 2023 Sep 20

PMID 37727423

Authors

Reza Beiranvand

Maryam Azimzadeh

Maryam Chegeni

Shahnaz Ghalavandi

Zahra Mohseni

Ehteram Yousefi

Zaher Khazaei

Yasan Kazemzadeh

Kaivan Gheysvandi

Elham Gheysvandi

Affiliations

Soon will be listed here.

Abstract

The current study aimed to determine the community-based COVID-19 prevalence and compare the symptom-based and test-based prevalence rates in the Omicron peak (February 20 to March 20, 2022) to assess community involvement and provide effective healthcare. This cross-sectional and population-based study examined the prevalence of COVID-19 from February 20 to March 20, 2022, in the city of Khomein in Markazi Province (located in central Iran) through random cluster sampling. The period prevalence of recurrent Omicron symptoms was 37.69%. Factors such as residence in urban areas (OR = 1.25, 95% CI: 0.95-1.66), number of COVID-19 vaccine doses (OR = 0.80, 95% CI: 0.67-0.95), the interval of last vaccination dose (OR = 1.04, 95% CI: 0.97-1.11) and a history of COVID-19 (OR =1.20, 95% CI: 1.04-1.39) were among the most important risk factors for Omicron. Ongoing efforts to vaccinate high-risk populations as well as stronger actions to diminish the Omicron consequences are fundamental obligations of the health system.

References

Accorsi E, Britton A, Fleming-Dutra K, Smith Z, Shang N, Derado G . Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA. 2022; 327(7):639-651. PMC: 8848203. DOI: 10.1001/jama.2022.0470. View

Leon T, Dorabawila V, Nelson L, Lutterloh E, Bauer U, Backenson B . COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021. MMWR Morb Mortal Wkly Rep. 2022; 71(4):125-131. PMC: 9351527. DOI: 10.15585/mmwr.mm7104e1. View

Morlock R, Morlock A, Downen M, Shah S . COVID-19 prevalence and predictors in United States adults during peak stay-at-home orders. PLoS One. 2021; 16(1):e0245586. PMC: 7822538. DOI: 10.1371/journal.pone.0245586. View

He X, Hong W, Pan X, Lu G, Wei X . SARS-CoV-2 Omicron variant: Characteristics and prevention. MedComm (2020). 2021; 2(4):838-845. PMC: 8693031. DOI: 10.1002/mco2.110. View

Meo S, Meo A, Al-Jassir F, Klonoff D . Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics. Eur Rev Med Pharmacol Sci. 2022; 25(24):8012-8018. DOI: 10.26355/eurrev_202112_27652. View

Buchan S, Chung H, Brown K, Austin P, Fell D, Gubbay J . Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes. JAMA Netw Open. 2022; 5(9):e2232760. PMC: 9500552. DOI: 10.1001/jamanetworkopen.2022.32760. View

Thompson M, Natarajan K, Irving S, Rowley E, Griggs E, Gaglani M . Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August.... MMWR Morb Mortal Wkly Rep. 2022; 71(4):139-145. PMC: 9351525. DOI: 10.15585/mmwr.mm7104e3. View

Tseng H, Ackerson B, Luo Y, Sy L, Talarico C, Tian Y . Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med. 2022; 28(5):1063-1071. PMC: 9117141. DOI: 10.1038/s41591-022-01753-y. View

Brussow H . COVID-19: Omicron - the latest, the least virulent, but probably not the last variant of concern of SARS-CoV-2. Microb Biotechnol. 2022; 15(7):1927-1939. PMC: 9111164. DOI: 10.1111/1751-7915.14064. View

10.

Sharma V, Rai H, Gautam D, Prajapati P, Sharma R . Emerging evidence on Omicron (B.1.1.529) SARS-CoV-2 variant. J Med Virol. 2022; 94(5):1876-1885. PMC: 9015596. DOI: 10.1002/jmv.27626. View

11.

Sheikh A, Kerr S, Woolhouse M, McMenamin J, Robertson C . Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design. Lancet Infect Dis. 2022; 22(7):959-966. PMC: 9033213. DOI: 10.1016/S1473-3099(22)00141-4. View

12.

Wu M, Wall E, Carr E, Harvey R, Townsley H, Mears H . Three-dose vaccination elicits neutralising antibodies against omicron. Lancet. 2022; 399(10326):715-717. PMC: 8769665. DOI: 10.1016/S0140-6736(22)00092-7. View

13.

Gao Y, Cai C, Grifoni A, Muller T, Niessl J, Olofsson A . Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant. Nat Med. 2022; 28(3):472-476. PMC: 8938268. DOI: 10.1038/s41591-022-01700-x. View

14.

Kannan S, Shaik Syed Ali P, Sheeza A . Omicron (B.1.1.529) - variant of concern - molecular profile and epidemiology: a mini review. Eur Rev Med Pharmacol Sci. 2022; 25(24):8019-8022. DOI: 10.26355/eurrev_202112_27653. View

15.

Maisa A, Spaccaferri G, Fournier L, Schaeffer J, Deniau J, Rolland P . First cases of Omicron in France are exhibiting mild symptoms, November 2021-January 2022. Infect Dis Now. 2022; 52(3):160-164. PMC: 9194534. DOI: 10.1016/j.idnow.2022.02.003. View